BD Announces Results For 2012 Fourth Fiscal Quarter And Full Year
-- Adjusted fourth-quarter diluted earnings per share from continuing operations of $1.42 exclude a $0.07 per share charge from primarily non-cash pension settlements; reported earnings per share from continuing operations were $1.35.
-- Expects full fiscal year 2013 reported diluted earnings per share from continuing operations to be between $5.58 and $5.64, an increase of 4 to 5 percent. On a foreign currency-neutral basis, expects earnings per share to grow between 7 to 8 percent, or 10 to 11 percent, after excluding the estimated impact of the medical device tax.
-- Results reflect reclassification of Discovery Labware unit, excluding Advanced Bioprocessing, as discontinued operations. The sale was completed on October 31, 2012.
FRANKLIN LAKES, N.J., Nov. 7, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.967 billion for the fourth fiscal quarter ended September 30, 2012, representing a decrease of 1.1 percent from the prior-year period, or an increase of 4.7 percent on a foreign currency-neutral basis.
For the full fiscal year ended September 30, 2012, BD reported revenues of $7.708 billion, representing an increase of 1.6 percent over the prior-year period or 4.3 percent on a foreign currency-neutral basis.
"We are proud of our solid finish to 2012," said Vincent A. Forlenza, Chairman of the Board, Chief Executive Officer and President. "Despite a challenging macroeconomic environment, we delivered on our financial and operating goals while continuing our ongoing investments in geographic expansion, new product platforms and strategic acquisitions. We believe we are well positioned to succeed and will continue to focus on our strategy of investing and innovating for growth. We are confident in our outlook for fiscal year 2013 and remain committed to delivering value to our customers and shareholders."
Sale of Discovery Labware Unit, Excluding Advanced Bioprocessing
In April 2012, the Company signed a definitive agreement to sell its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platform, to Corning Incorporated. The results of operations associated with this disposal group have been reclassified as discontinued operations for all quarters and years referred to in this release. The transaction was completed on October 31, 2012 and the Company will record a gain within discontinued operations in the first quarter of fiscal year 2013.
Fourth Quarter and Analysis of the Full Fiscal Year 2012 and 2011 Earnings
Reported diluted earnings per share from continuing operations for the fourth quarter were $1.35, representing an increase of 4.7 percent over the prior-year period. Current quarter results included a charge of $20 million, or $0.07 per share from continuing operations, resulting from primarily non-cash pension settlements. The prior-year period results included a non-cash charge of $9 million, or $0.03 per share from continuing operations, resulting from the discontinuance of a research program within the Diagnostic Systems unit. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 7.6 percent to $1.42, compared with $1.32 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fourth quarter increased by 15.2 percent.
For the full fiscal year ended September 30, 2012, reported diluted earnings per share from continuing operations were $5.30, representing a decrease of 0.2 percent over the prior-year period. Excluding the aforementioned charges of $0.06 per share from continuing operations in fiscal year 2012, and $0.03 per share from continuing operations in fiscal year 2011, adjusted diluted earnings per share from continuing operations increased by 0.8 percent to $5.37, compared with $5.33 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the fiscal year increased 4.7 percent. On a full year basis, the charge of $20 million, or $0.06 per share from continuing operations, differs from the charge in the fourth quarter of $0.07 per share from continuing operations due to the number of average shares outstanding between the fourth quarter and full year.
Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.049 billion, representing a decrease of 0.5 percent compared with the prior-year period, or an increase of 5.9 percent on a currency-neutral basis. The segment's revenue growth reflected strong sales across all three business units. For the twelve-month period ended September 30, 2012, BD Medical revenues increased 2.1 percent, or 5.1 percent on a currency-neutral basis.
In the BD Diagnostics segment, worldwide revenues for the quarter were $645 million, representing an increase of 0.5 percent compared with the prior-year period, or 5.1 percent on a foreign currency-neutral basis. The segment's growth was primarily driven by solid sales of Preanalytical Systems safety-engineered products and strong sales in the Diagnostic Systems unit, aided by the recent acquisition of KIESTRA. For the twelve-month period ended September 30, 2012, BD Diagnostics revenues increased 2.3 percent, or 4.5 percent on a currency-neutral basis.
In the BD Biosciences segment, worldwide revenues for the quarter were $273 million, representing a decrease of 6.3 percent compared with the prior-year period, or 0.7 percent on a foreign currency-neutral basis. Segment results continue to be negatively affected by weakness in the U.S. research market. For the twelve-month period ended September 30, 2012, BD Biosciences revenues decreased by 1.5 percent. On a foreign currency-neutral basis, revenues increased by 0.7 percent.
Geographic Results
Fourth quarter revenues in the U.S. were $824 million, representing an increase of 1.2 percent compared with the prior-year period. Revenues outside of the U.S. were $1.143 billion, representing a decrease of 2.6 percent compared with the prior-year period, or an increase of 7.1 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products. For the twelve-month period ended September 30, 2012, revenues in the U.S. were $3.288 billion, representing an increase of 1.2 percent compared with the prior-year period. Revenues outside of the U.S. were $4.421 billion, representing an increase of 1.9 percent compared with the prior-year period, or 6.6 percent on a foreign currency-neutral basis.
Fiscal 2013 Outlook for Full Year
The Company estimates that reported revenues for the full fiscal year 2013 will increase 2 to 3 percent, or about 3.5 to 4.5 percent on a foreign currency-neutral basis. The Company expects reported diluted earnings per share from continuing operations for the full fiscal year 2013 to be between $5.58 and $5.64. On a currency-neutral basis, the Company expects diluted earnings per share from continuing operations to grow 7 to 8 percent, or 10 to 11 percent excluding the impact of the medical device tax that goes into effect in January 2013 under the U.S. healthcare reform law. The Company also plans to repurchase, subject to market conditions, about $500 million of its common stock in 2013.
Conference Call Information
A conference call regarding BD's fourth quarter and full-year results and its expectations for the full fiscal year 2013 will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Wednesday, November 7, 2012. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Wednesday, November 14, 2012, access code 35734482.
Non-GAAP Financial Measures
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Contact:
Monique N. Dolecki, Investor Relations – 201-847-5378
Colleen T. White, Corporate Communications – 201-847-5369
This press release, including the section entitled "Fiscal 2013 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; changes in interest or foreign currency exchange rates; competitive factors; pricing and other market pressures; our ability to successfully integrate any businesses we acquire; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
|
BECTON DICKINSON AND COMPANY | |||||||
|
CONSOLIDATED INCOME STATEMENTS | |||||||
|
(Unaudited; Amounts in thousands, except per share data) | |||||||
|
Three Months Ended September 30, | |||||||
|
2012 |
2011 |
% Change | |||||
|
REVENUES |
$ |
1,967,171 |
$ |
1,988,181 |
(1.1) | ||
|
Cost of products sold |
966,345 |
971,041 |
(0.5) | ||||
|
Selling and administrative |
484,259 |
479,591 |
1.0 | ||||
|
Research and development |
127,787 |
124,528 |
2.6 | ||||
|
TOTAL OPERATING COSTS |
|||||||
|
AND EXPENSES |
1,578,391 |
1,575,160 |
0.2 | ||||
|
OPERATING INCOME |
388,780 |
413,021 |
(5.9) | ||||
|
Interest income |
11,954 |
1,915 |
NM | ||||
|
Interest expense |
(35,292) |
(22,334) |
58.0 | ||||
|
Other (expense) income, net |
(3,543) |
1,272 |
NM | ||||
|
INCOME FROM CONTINUING OPERATIONS BEFORE |
|||||||
|
INCOME TAXES |
361,899 |
393,874 |
(8.1) | ||||
|
Income tax provision |
87,621 |
108,827 |
(19.5) | ||||
|
INCOME FROM CONTINUING OPERATIONS |
274,278 |
285,047 |
(3.8) | ||||
|
INCOME FROM DISCONTINUED OPERATIONS |
|||||||
|
NET OF INCOME TAX PROVISION OF |
|||||||
|
$9,108 AND $8,860, RESPECTIVELY |
14,765 |
14,933 |
(1.1) | ||||
|
NET INCOME |
$ |
289,043 |
$ |
299,980 |
(3.6) | ||
|
EARNINGS PER SHARE |
|||||||
|
Basic: |
|||||||
|
Income from continuing operations |
$ |
1.38 |
$ |
1.32 |
4.5 | ||
|
Income from discontinued operations |
$ |
0.07 |
$ |
0.07 |
- | ||
|
Net income (1) |
$ |
1.45 |
$ |
1.38 |
5.1 | ||
|
Diluted: |
|||||||
|
Income from continuing operations |
$ |
1.35 |
$ |
1.29 |
4.7 | ||
|
Income from discontinued operations |
$ |
0.07 |
$ |
0.07 |
- | ||
|
Net income (1) |
$ |
1.43 |
$ |
1.36 |
5.1 | ||
|
AVERAGE SHARES OUTSTANDING |
|||||||
|
Basic |
199,072 |
216,726 |
|||||
|
Diluted |
202,439 |
220,859 |
|||||
|
NM - Not Meaningful |
|||||||
|
(1) Total per share amounts may not add due to rounding. |
|||||||
|
BECTON DICKINSON AND COMPANY | |||||||
|
CONSOLIDATED INCOME STATEMENTS | |||||||
|
(Unaudited; Amounts in thousands, except per share data) | |||||||
|
Twelve Months Ended September 30, | |||||||
|
2012 |
2011 |
% Change | |||||
|
REVENUES |
$ |
7,708,382 |
$ |
7,584,037 |
1.6 | ||
|
Cost of products sold |
3,755,388 |
3,625,122 |
3.6 | ||||
|
Selling and administrative |
1,923,354 |
1,823,537 |
5.5 | ||||
|
Research and development |
471,755 |
469,517 |
0.5 | ||||
|
TOTAL OPERATING COSTS |
|||||||
|
AND EXPENSES |
6,150,497 |
5,918,176 |
3.9 | ||||
|
OPERATING INCOME |
1,557,885 |
1,665,861 |
(6.5) | ||||
|
Interest income |
50,333 |
43,209 |
16.5 | ||||
|
Interest expense |
(134,658) |
(84,019) |
60.3 | ||||
|
Other expense, net |
(1,152) |
(7,164) |
(83.9) | ||||
|
INCOME FROM CONTINUING OPERATIONS BEFORE |
|||||||
|
INCOME TAXES |
1,472,408 |
1,617,887 |
(9.0) | ||||
|
Income tax provision |
362,880 |
417,004 |
(13.0) | ||||
|
INCOME FROM CONTINUING OPERATIONS |
1,109,528 |
1,200,883 |
(7.6) | ||||
|
INCOME FROM DISCONTINUED OPERATIONS |
|||||||
|
NET OF INCOME TAX PROVISION OF |
|||||||
|
$31,268 AND $35,199, RESPECTIVELY |
60,399 |
70,111 |
(13.9) | ||||
|
NET INCOME |
$ |
1,169,927 |
$ |
1,270,994 |
(8.0) | ||
|
EARNINGS PER SHARE |
|||||||
|
Basic: |
|||||||
|
Income from continuing operations |
$ |
5.40 |
$ |
5.43 |
(0.6) | ||
|
Income from discontinued operations |
$ |
0.29 |
$ |
0.32 |
(9.4) | ||
|
Net income |
$ |
5.69 |
$ |
5.75 |
(1.0) | ||
|
Diluted: |
|||||||
|
Income from continuing operations |
$ |
5.30 |
$ |
5.31 |
(0.2) | ||
|
Income from discontinued operations |
$ |
0.29 |
$ |
0.31 |
(6.5) | ||
|
Net income |
$ |
5.59 |
$ |
5.62 |
(0.5) | ||
|
AVERAGE SHARES OUTSTANDING |
|||||||
|
Basic |
205,460 |
221,175 |
|||||
|
Diluted |
209,181 |
226,280 |
|||||
|
Becton Dickinson and Company | ||||||
|
Supplemental Income Statement Information - Fiscal 2012 | ||||||
|
Revised for discontinued operations of Discovery Labware divestiture | ||||||
|
(Unaudited: Amounts in thousands, except per-share data) | ||||||
|
Amounts |
||||||
|
reclassified to |
From | |||||
|
Discontinued |
Continuing | |||||
|
Pro Forma |
Operations |
Operations | ||||
|
Quarter 1 |
||||||
|
Revenues |
$ |
1,887,645 |
$ |
55,925 |
$ |
1,831,720 |
|
Income |
$ |
263,010 |
$ |
14,466 |
$ |
248,544 |
|
Diluted Earnings Per Share |
$ |
1.21 |
$ |
0.07 |
$ |
1.14 |
|
Quarter 2 |
||||||
|
Revenues |
$ |
1,990,818 |
$ |
61,857 |
$ |
1,928,961 |
|
Income |
$ |
290,548 |
$ |
15,424 |
$ |
275,124 |
|
Diluted Earnings Per Share |
$ |
1.38 |
$ |
0.07 |
$ |
1.31 |
|
Quarter 3 |
||||||
|
Revenues |
$ |
2,040,760 |
$ |
60,230 |
$ |
1,980,530 |
|
Income |
$ |
326,795 |
$ |
15,214 |
$ |
311,581 |
|
Diluted Earnings Per Share |
$ |
1.59 |
$ |
0.07 |
$ |
1.52 |
|
Quarter 4 |
||||||
|
Revenues |
$ |
2,027,335 |
$ |
60,164 |
$ |
1,967,171 |
|
Income |
$ |
289,099 |
$ |
14,821 |
$ |
274,278 |
|
Diluted Earnings Per Share (1) |
$ |
1.43 |
$ |
0.07 |
$ |
1.35 |
|
YTD |
||||||
|
Revenues |
$ |
7,946,559 |
$ |
238,177 |
$ |
7,708,382 |
|
Income |
$ |
1,169,453 |
$ |
59,925 |
$ |
1,109,528 |
|
Diluted Earnings Per Share |
$ |
5.59 |
$ |
0.29 |
$ |
5.30 |
|
Certain quarterly amounts may not add to the year-to-date totals due to rounding. | ||||||
|
(1) Diluted Earnings per Share may not add due to rounding. | ||||||
|
Becton Dickinson and Company | ||||||
|
Supplemental Income Statement Information - Fiscal 2011 and 2010 | ||||||
|
Revised for discontinued operations of Discovery Labware divestiture | ||||||
|
(Unaudited: Amounts in thousands, except per-share data) | ||||||
|
Amounts |
||||||
|
reclassified to |
From | |||||
|
Discontinued |
Continuing | |||||
|
Pro Forma |
Operations |
Operations | ||||
|
Fiscal 2011 |
||||||
|
Revenues |
$ |
7,828,904 |
$ |
244,867 |
$ |
7,584,037 |
|
Income |
$ |
1,264,852 |
$ |
63,969 |
$ |
1,200,883 |
|
Diluted Earnings Per Share |
$ |
5.59 |
$ |
0.28 |
$ |
5.31 |
|
Fiscal 2010 |
||||||
|
Revenues |
$ |
7,372,333 |
$ |
247,948 |
$ |
7,124,385 |
|
Income |
$ |
1,176,340 |
$ |
61,496 |
$ |
1,114,844 |
|
Diluted Earnings Per Share |
$ |
4.90 |
$ |
0.26 |
$ |
4.64 |
|
BECTON DICKINSON AND COMPANY | |||||||
|
SUPPLEMENTAL REVENUE INFORMATION | |||||||
|
REVENUES BY SEGMENT AND GEOGRAPHIC AREA | |||||||
|
(Unaudited; Amounts in thousands) | |||||||
|
Three Months Ended September 30, | |||||||
|
2012 |
2011 |
% Change | |||||
|
BD MEDICAL |
|||||||
|
United States |
$ |
422,290 |
$ |
404,301 |
4.4 | ||
|
International |
626,742 |
650,290 |
(3.6) | ||||
|
TOTAL |
$ |
1,049,032 |
$ |
1,054,591 |
(0.5) | ||
|
BD DIAGNOSTICS |
|||||||
|
United States |
$ |
313,916 |
$ |
313,603 |
0.1 | ||
|
International |
331,128 |
328,445 |
0.8 | ||||
|
TOTAL |
$ |
645,044 |
$ |
642,048 |
0.5 | ||
|
BD BIOSCIENCES |
|||||||
|
United States |
$ |
87,651 |
$ |
96,543 |
(9.2) | ||
|
International |
185,444 |
194,999 |
(4.9) | ||||
|
TOTAL |
$ |
273,095 |
$ |
291,542 |
(6.3) | ||
|
TOTAL REVENUES |
|||||||
|
United States |
$ |
823,857 |
$ |
814,447 |
1.2 | ||
|
International |
1,143,314 |
1,173,734 |
(2.6) | ||||
|
TOTAL |
$ |
1,967,171 |
$ |
1,988,181 |
(1.1) | ||
|
BECTON DICKINSON AND COMPANY | |||||||
|
SUPPLEMENTAL REVENUE INFORMATION | |||||||
|
REVENUES BY SEGMENT AND GEOGRAPHIC AREA | |||||||
|
(Unaudited; Amounts in thousands) | |||||||
|
Twelve Months Ended September 30, | |||||||
|
2012 |
2011 |
% Change | |||||
|
BD MEDICAL |
|||||||
|
United States |
$ |
1,685,101 |
$ |
1,625,044 |
3.7 | ||
|
International |
2,405,592 |
2,382,260 |
1.0 | ||||
|
TOTAL |
$ |
4,090,693 |
$ |
4,007,304 |
2.1 | ||
|
BD DIAGNOSTICS |
|||||||
|
United States |
$ |
1,259,376 |
$ |
1,245,872 |
1.1 | ||
|
International |
1,278,679 |
1,234,605 |
3.6 | ||||
|
TOTAL |
$ |
2,538,055 |
$ |
2,480,477 |
2.3 | ||
|
BD BIOSCIENCES |
|||||||
|
United States |
$ |
343,238 |
$ |
376,639 |
(8.9) | ||
|
International |
736,396 |
719,617 |
2.3 | ||||
|
TOTAL |
$ |
1,079,634 |
$ |
1,096,256 |
(1.5) | ||
|
TOTAL REVENUES |
|||||||
|
United States |
$ |
3,287,715 |
$ |
3,247,555 |
1.2 | ||
|
International |
4,420,667 |
4,336,482 |
1.9 | ||||
|
TOTAL |
$ |
7,708,382 |
$ |
7,584,037 |
1.6 | ||
|
BECTON DICKINSON AND COMPANY | ||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS | ||||||
|
Three Months Ended September 30, | ||||||
|
(Unaudited; Amounts in thousands) | ||||||
|
United States | ||||||
|
2012 |
2011 |
% Change | ||||
|
BD MEDICAL |
||||||
|
Medical Surgical Systems |
$ |
250,664 |
$ |
246,746 |
1.6 | |
|
Diabetes Care |
113,046 |
104,819 |
7.8 | |||
|
Pharmaceutical Systems |
58,580 |
52,736 |
11.1 | |||
|
TOTAL |
$ |
422,290 |
$ |
404,301 |
4.4 | |
|
BD DIAGNOSTICS |
||||||
|
Preanalytical Systems |
$ |
164,856 |
$ |
161,556 |
2.0 | |
|
Diagnostic Systems |
149,060 |
152,047 |
(2.0) | |||
|
TOTAL |
$ |
313,916 |
$ |
313,603 |
0.1 | |
|
BD BIOSCIENCES (1) |
$ |
87,651 |
$ |
96,543 |
(9.2) | |
|
TOTAL UNITED STATES |
$ |
823,857 |
$ |
814,447 |
1.2 | |
|
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform. | ||||||
|
Advanced Bioprocessing was previously reported with the Discovery Labware unit. | ||||||
|
BECTON DICKINSON AND COMPANY | ||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS | ||||||||||
|
Three Months Ended September 30, (continued) | ||||||||||
|
(Unaudited; Amounts in thousands) | ||||||||||
|
International | ||||||||||
|
% Change | ||||||||||
|
2012 |
2011 |
Reported |
FXN |
FX Impact | ||||||
|
BD MEDICAL |
||||||||||
|
Medical Surgical Systems |
$ |
281,603 |
$ |
288,653 |
(2.4) |
6.8 |
(9.2) | |||
|
Diabetes Care |
120,391 |
119,832 |
0.5 |
9.8 |
(9.3) | |||||
|
Pharmaceutical Systems |
224,748 |
241,805 |
(7.1) |
5.3 |
(12.4) | |||||
|
TOTAL |
$ |
626,742 |
$ |
650,290 |
(3.6) |
6.8 |
(10.4) | |||
|
BD DIAGNOSTICS |
||||||||||
|
Preanalytical Systems |
$ |
162,648 |
$ |
167,044 |
(2.6) |
7.3 |
(9.9) | |||
|
Diagnostic Systems |
168,480 |
161,401 |
4.4 |
12.7 |
(8.3) | |||||
|
TOTAL |
$ |
331,128 |
$ |
328,445 |
0.8 |
9.9 |
(9.1) | |||
|
BD BIOSCIENCES (1) |
$ |
185,444 |
$ |
194,999 |
(4.9) |
3.5 |
(8.4) | |||
|
TOTAL INTERNATIONAL |
$ |
1,143,314 |
$ |
1,173,734 |
(2.6) |
7.1 |
(9.7) | |||
|
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform. | ||||||||||
|
Advanced Bioprocessing was previously reported with the Discovery Labware unit. | ||||||||||
|
BECTON DICKINSON AND COMPANY | ||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS | ||||||||||
|
Three Months Ended September 30, (continued) | ||||||||||
|
(Unaudited; Amounts in thousands) | ||||||||||
|
Total | ||||||||||
|
% Change | ||||||||||
|
2012 |
2011 |
Reported |
FXN |
FX Impact | ||||||
|
BD MEDICAL |
||||||||||
|
Medical Surgical Systems |
$ |
532,267 |
$ |
535,399 |
(0.6) |
4.4 |
(5.0) | |||
|
Diabetes Care |
233,437 |
224,651 |
3.9 |
8.9 |
(5.0) | |||||
|
Pharmaceutical Systems |
283,328 |
294,541 |
(3.8) |
6.4 |
(10.2) | |||||
|
TOTAL |
$ |
1,049,032 |
$ |
1,054,591 |
(0.5) |
5.9 |
(6.4) | |||
|
BD DIAGNOSTICS |
||||||||||
|
Preanalytical Systems |
$ |
327,504 |
$ |
328,600 |
(0.3) |
4.7 |
(5.0) | |||
|
Diagnostic Systems |
317,540 |
313,448 |
1.3 |
5.6 |
(4.3) | |||||
|
TOTAL |
$ |
645,044 |
$ |
642,048 |
0.5 |
5.1 |
(4.6) | |||
|
BD BIOSCIENCES (1) |
$ |
273,095 |
$ |
291,542 |
(6.3) |
(0.7) |
(5.6) | |||
|
TOTAL REVENUES |
$ |
1,967,171 |
$ |
1,988,181 |
(1.1) |
4.7 |
(5.8) | |||
|
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform. | ||||||||||
|
Advanced Bioprocessing was previously reported with the Discovery Labware unit. | ||||||||||
|
BECTON DICKINSON AND COMPANY | ||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS | ||||||
|
Twelve Months Ended September 30, | ||||||
|
(Unaudited; Amounts in thousands) | ||||||
|
United States | ||||||
|
2012 |
2011 |
% Change | ||||
|
BD MEDICAL |
||||||
|
Medical Surgical Systems |
$ |
977,999 |
$ |
980,326 |
(0.2) | |
|
Diabetes Care |
434,310 |
400,809 |
8.4 | |||
|
Pharmaceutical Systems |
272,792 |
243,909 |
11.8 | |||
|
TOTAL |
$ |
1,685,101 |
$ |
1,625,044 |
3.7 | |
|
BD DIAGNOSTICS |
||||||
|
Preanalytical Systems |
$ |
656,389 |
$ |
643,180 |
2.1 | |
|
Diagnostic Systems |
602,987 |
602,692 |
0.0 | |||
|
TOTAL |
$ |
1,259,376 |
$ |
1,245,872 |
1.1 | |
|
BD BIOSCIENCES (1) |
$ |
343,238 |
$ |
376,639 |
(8.9) | |
|
TOTAL UNITED STATES |
$ |
3,287,715 |
$ |
3,247,555 |
1.2 | |
|
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform. | ||||||
|
Advanced Bioprocessing was previously reported with the Discovery Labware unit. | ||||||
|
BECTON DICKINSON AND COMPANY | ||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS | ||||||||||
|
Twelve Months Ended September 30, (continued) | ||||||||||
|
(Unaudited; Amounts in thousands) | ||||||||||
|
International | ||||||||||
|
% Change | ||||||||||
|
2012 |
2011 |
Reported |
FXN |
FX Impact | ||||||
|
BD MEDICAL |
||||||||||
|
Medical Surgical Systems |
$ |
1,127,289 |
$ |
1,101,407 |
2.3 |
6.9 |
(4.6) | |||
|
Diabetes Care |
476,966 |
465,668 |
2.4 |
6.8 |
(4.4) | |||||
|
Pharmaceutical Systems |
801,337 |
815,185 |
(1.7) |
4.4 |
(6.1) | |||||
|
TOTAL |
$ |
2,405,592 |
$ |
2,382,260 |
1.0 |
6.1 |
(5.1) | |||
|
BD DIAGNOSTICS |
||||||||||
|
Preanalytical Systems |
$ |
644,503 |
$ |
634,613 |
1.6 |
6.7 |
(5.1) | |||
|
Diagnostic Systems |
634,176 |
599,992 |
5.7 |
9.4 |
(3.7) | |||||
|
TOTAL |
$ |
1,278,679 |
$ |
1,234,605 |
3.6 |
8.0 |
(4.4) | |||
|
BD BIOSCIENCES (1) |
$ |
736,396 |
$ |
719,617 |
2.3 |
5.8 |
(3.5) | |||
|
TOTAL INTERNATIONAL |
$ |
4,420,667 |
$ |
4,336,482 |
1.9 |
6.6 |
(4.7) | |||
|
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform. | ||||||||||
|
Advanced Bioprocessing was previously reported with the Discovery Labware unit. | ||||||||||
|
BECTON DICKINSON AND COMPANY | ||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||||||
|
REVENUES BY BUSINESS SEGMENTS AND UNITS | ||||||||||
|
Twelve Months Ended September 30, (continued) | ||||||||||
|
(Unaudited; Amounts in thousands) | ||||||||||
|
Total | ||||||||||
|
% Change | ||||||||||
|
2012 |
2011 |
Reported |
FXN |
FX Impact | ||||||
|
BD MEDICAL |
||||||||||
|
Medical Surgical Systems |
$ |
2,105,288 |
$ |
2,081,733 |
1.1 |
3.6 |
(2.5) | |||
|
Diabetes Care |
911,276 |
866,477 |
5.2 |
7.5 |
(2.3) | |||||
|
Pharmaceutical Systems |
1,074,129 |
1,059,094 |
1.4 |
6.2 |
(4.8) | |||||
|
TOTAL |
$ |
4,090,693 |
$ |
4,007,304 |
2.1 |
5.1 |
(3.0) | |||
|
BD DIAGNOSTICS |
||||||||||
|
Preanalytical Systems |
$ |
1,300,892 |
$ |
1,277,793 |
1.8 |
4.3 |
(2.5) | |||
|
Diagnostic Systems |
1,237,163 |
1,202,684 |
2.9 |
4.7 |
(1.8) | |||||
|
TOTAL |
$ |
2,538,055 |
$ |
2,480,477 |
2.3 |
4.5 |
(2.2) | |||
|
BD BIOSCIENCES (1) |
$ |
1,079,634 |
$ |
1,096,256 |
(1.5) |
0.7 |
(2.2) | |||
|
TOTAL REVENUES |
$ |
7,708,382 |
$ |
7,584,037 |
1.6 |
4.3 |
(2.7) | |||
|
(1) BD Biosciences consists of the Cell Analysis unit and the Advanced Bioprocessing platform. | ||||||||||
|
Advanced Bioprocessing was previously reported with the Discovery Labware unit. | ||||||||||
|
BECTON DICKINSON AND COMPANY | ||||||||||
|
SUPPLEMENTAL REVENUE INFORMATION | ||||||||||
|
SAFETY REVENUES | ||||||||||
|
(Unaudited; Amounts in thousands) | ||||||||||
|
Three Months Ended September 30, | ||||||||||
|
% Change | ||||||||||
|
2012 |
2011 |
Reported |
FXN |
FX Impact | ||||||
|
TOTAL SAFETY REVENUES |
||||||||||
|
United States |
$ |
291,046 |
$ |
288,541 |
0.9 |
0.9 |
- | |||
|
International |
215,595 |
209,209 |
3.1 |
12.7 |
(9.6) | |||||
|
TOTAL |
$ |
506,641 |
$ |
497,750 |
1.8 |
5.8 |
(4.0) | |||
|
BY SEGMENT |
||||||||||
|
BD Medical |
$ |
250,676 |
$ |
243,521 |
2.9 |
6.4 |
(3.5) | |||
|
BD Diagnostics |
255,965 |
254,229 |
0.7 |
5.3 |
(4.6) | |||||
|
TOTAL |
$ |
506,641 |
$ |
497,750 |
1.8 |
5.8 |
(4.0) | |||
|
Twelve Months Ended September 30, | ||||||||||
|
% Change | ||||||||||
|
2012 |
2011 |
Reported |
FXN |
FX Impact | ||||||
|
TOTAL SAFETY REVENUES |
||||||||||
|
United States |
$ |
1,149,220 |
$ |
1,116,543 |
2.9 |
2.9 |
- | |||
|
International |
833,886 |
754,739 |
10.5 |
15.6 |
(5.1) | |||||
|
TOTAL |
$ |
1,983,106 |
$ |
1,871,282 |
6.0 |
8.0 |
(2.0) | |||
|
BY SEGMENT |
||||||||||
|
BD Medical |
$ |
966,452 |
$ |
885,156 |
9.2 |
10.8 |
(1.6) | |||
|
BD Diagnostics |
1,016,654 |
986,126 |
3.1 |
5.6 |
(2.5) | |||||
|
TOTAL |
$ |
1,983,106 |
$ |
1,871,282 |
6.0 |
8.0 |
(2.0) | |||
|
BECTON DICKINSON AND COMPANY | ||||||||||||||
|
SUPPLEMENTAL INFORMATION | ||||||||||||||
|
FY2012 Quarter-to-Date Reconciliation | ||||||||||||||
|
(Unaudited; Amounts in millions, except per share data) | ||||||||||||||
|
Three Months Ended September 30, | ||||||||||||||
|
Reported |
Pension Settlement |
Adjusted |
Reported |
Impairment |
Adjusted |
Adjusted | ||||||||
|
FY 2012 |
Charge(1) |
FY 2012 |
FY 2011 |
Charge(2) |
FY 2011 |
%Growth | ||||||||
|
Diluted Earnings per Share |
||||||||||||||
|
from Continuing Operations |
$ |
1.35 |
$ |
0.07 |
$ |
1.42 |
$ |
1.29 |
0.03 |
$ |
1.32 |
7.6% | ||
|
(1) Primarily represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's | ||||||||||||||
|
U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. | ||||||||||||||
|
The charge also included settlement losses associated with certain foreign pension plans. | ||||||||||||||
|
(2)Represents a non-cash impairment charge resulting from the discontinuance of a research program within the Diagnostic Systems unit. | ||||||||||||||
|
All figures rounded. Totals may not add due to rounding. | ||||||||||||||
|
BECTON DICKINSON AND COMPANY | ||||||||||||||
|
SUPPLEMENTAL INFORMATION | ||||||||||||||
|
FY2012 Year-to-Date Reconciliation | ||||||||||||||
|
(Unaudited; Amounts in millions, except per share data) | ||||||||||||||
|
Twelve Months Ended September 30, | ||||||||||||||
|
Reported |
Pension Settlement |
Adjusted |
Reported |
Impairment |
Adjusted |
Adjusted | ||||||||
|
FY 2012 |
Charge(1) |
FY 2012 |
FY 2011 |
Charge(2) |
FY 2011 |
%Growth | ||||||||
|
Diluted Earnings per Share |
||||||||||||||
|
from Continuing Operations |
$ |
5.30 |
$ |
0.06 |
$ |
5.37 |
$ |
5.31 |
$ |
0.03 |
$ |
5.33 |
0.8% | |
|
(1) Primarily represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's | ||||||||||||||
|
U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. | ||||||||||||||
|
The charge also included settlement losses associated with certain foreign pension plans. | ||||||||||||||
|
(2)Represents a non-cash impairment charge resulting from the | ||||||||||||||
|
discontinuance of a research program within the Diagnostic Systems unit. | ||||||||||||||
|
All figures rounded. Totals may not add due to rounding. | ||||||||||||||
|
BECTON DICKINSON AND COMPANY | |||||||||||||
|
SUPPLEMENTAL INFORMATION | |||||||||||||
|
Quarter-to-Date Fiscal 2012 Reconciliation - FX Impact | |||||||||||||
|
(Unaudited; Amounts in millions, except per share data) | |||||||||||||
|
Three Months Ended September 30, | |||||||||||||
|
Adjusted |
Adjusted |
Adjusted Growth |
Foreign Currency |
FXN |
FXN | ||||||||
|
FY 2012 |
FY 2011 |
$ |
Translation |
Change |
Growth | ||||||||
|
REVENUES |
$ |
1,967 |
$ |
1,988 |
$ |
(21) |
$ |
(114) |
$ |
93 |
4.7% | ||
|
Diluted Earnings per Share |
|||||||||||||
|
from Continuing Operations |
$ |
1.42 |
$ |
1.32 |
$ |
0.10 |
$ |
(0.10) |
$ |
0.20 |
15.2% | ||
|
FXN - Foreign Currency Neutral | |||||||||||||
|
All figures rounded. Totals may not add due to rounding. | |||||||||||||
|
BECTON DICKINSON AND COMPANY | |||||||||||||
|
SUPPLEMENTAL INFORMATION | |||||||||||||
|
Year-to-Date Fiscal 2012 Reconciliation - FX Impact | |||||||||||||
|
(Unaudited; Amounts in millions, except per share data) | |||||||||||||
|
Twelve Months Ended September 30, | |||||||||||||
|
Adjusted |
Adjusted |
Adjusted Growth |
Foreign Currency |
FXN |
FXN | ||||||||
|
FY 2012 |
FY 2011 |
$ |
Translation |
Change |
Growth | ||||||||
|
REVENUES |
$ |
7,708 |
$ |
7,584 |
$ |
124 |
$ |
(200) |
$ |
325 |
4.3% | ||
|
Diluted Earnings per Share |
|||||||||||||
|
from Continuing Operations |
$ |
5.37 |
$ |
5.33 |
$ |
0.04 |
$ |
(0.21) |
$ |
0.25 |
4.7% | ||
|
FXN - Foreign Currency Neutral | |||||||||||||
|
All figures rounded. Totals may not add due to rounding. | |||||||||||||
|
BECTON DICKINSON AND COMPANY | ||||
|
SUPPLEMENTAL INFORMATION | ||||
|
FY2013 Outlook Reconciliation | ||||
|
EPS |
Revenues | |||
|
Growth |
4-5% |
2-3% | ||
|
FX impact |
(3%) |
(1.5%) | ||
|
FX neutral growth |
7-8% |
3.5%-4.5% | ||
|
Device tax impact |
(3%) |
|||
|
10-11% |
||||
SOURCE BD (Becton, Dickinson and Company)
Share this article